TriangleCD371-specific/YSNVz/I-18 CAR T cells (NCT06017258)
CD371-specific/YSNVz/I-18 CAR T cells trial for Refractory Acute Myeloid Leukemia (NCT06017258). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
CAR T cells transformed lymphoid leukemias. In acute myeloid leukemia they have mostly failed: the cells tire, and the leukemia carries on.
The idea: a receptor built to resist exhaustion, on cells that also pump out their own alarm signal.
At Memorial Sloan Kettering, a patient's T cells get a receptor for CD371, a marker on AML cells, with an altered signaling domain to slow burnout, plus a gene to secrete interleukin-18, which rallies other immune cells.
In the first five patients, the cells expanded from one small infusion. Three, each refractory to five or more prior treatments, cleared their leukemia. Two at the higher dose had serious side effects, so the dose was reduced.
Mark Geyer leads it. Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.